Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label Study of the Effect of First Line Treatment With Tarceva in Sequential Combination With Gemcitabine, Compared to Gemcitabine Monotherapy, on Progression-free Survival in Elderly or ECOG PS of 2 Patients With Advanced Non-small Cell Lung Cancer.
Conditions
Interventions
erlotinib [Tarceva]
gemcitabine
+1 more
Locations
17
Australia
Port Macquarie, New South Wales, Australia
Randwick, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Tweed Heads, New South Wales, Australia
Wollongong, New South Wales, Australia
Start Date
June 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
April 2, 2015
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions